HER2Δ16 expression in HER2-positive breast cancer

被引：0
|
作者：
De Yao, Jocelyn Torres
Sun, Danyu
Galehouse, Donna
Shorten, Scott
Haller, Nairmeen
Rehmus, Esther Hoogland
机构：
[1] Allegheny Hlth Network, West Penn Allegheny Hlth Syst, Pittsburgh, PA USA
[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[3] Akron Childrens Hosp, Akron, OH USA
[4] Akron Gen Med Ctr, Akron, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e11599
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11599
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen Awad
    Rehmus, Esther Hoogland
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [2] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [3] Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
    Maria, Alaa Mohamed
    El-Shebiney, Mohamed
    El-Saka, Ayman Mohamed
    Zamzam, Yomna
    [J]. JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (02) : 49 - 55
  • [4] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    [J]. BMC CANCER, 2022, 22 (01)
  • [5] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    [J]. BMC Cancer, 22
  • [6] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Endo, Yumi
    Dong, Yu
    Kondo, Naoto
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Nishimoto, Mayumi
    Kato, Hiroyuki
    Takahashi, Satoru
    Nakanishi, Ryoichi
    Toyama, Tatsuya
    [J]. BREAST CANCER, 2016, 23 (06) : 902 - 907
  • [7] HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
    Hosonaga, Mari
    Arima, Yoshimi
    Sampetrean, Oltea
    Komura, Daisuke
    Koya, Ikuko
    Sasaki, Takashi
    Sato, Eiichi
    Okano, Hideyuki
    Kudoh, Jun
    Ishikawa, Shumpei
    Saya, Hideyuki
    Ishikawa, Takashi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [8] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Yumi Endo
    Yu Dong
    Naoto Kondo
    Nobuyasu Yoshimoto
    Tomoko Asano
    Yukari Hato
    Mayumi Nishimoto
    Hiroyuki Kato
    Satoru Takahashi
    Ryoichi Nakanishi
    Tatsuya Toyama
    [J]. Breast Cancer, 2016, 23 : 902 - 907
  • [9] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [10] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
12345